Ahmed Kotb/LinkedIn
Aug 18, 2025, 23:49
Ahmed Kotb: HHT Management—Choosing the Right Therapy?
Ahmed Kotb, Head of Global Oncology Medical Affairs at Daiichi Sankyo, shared on X:
“HHT management (guideline highlights):
- Epistaxis → Topical + Antifibrinolytics → Anti-angiogenic if refractory
- GI bleed → Grade by iron/RBC needs → (mild) → (moderate–severe)
- Anemia → Screen → Oral iron → IV iron.”
More on coagulation disorders featured in Hemostasis Today.
-
Jul 10, 2026, 20:47New Machine Learning Models Improve Prediction of Thrombosis and Bleeding in Cancer – JTH
-
Jul 10, 2026, 20:39Evangelia Petsalaki: New Systems Biology Approach Identifies Biomarkers in Thrombotic APS
-
Jul 10, 2026, 20:29Wolfgang Miesbach: Celebrating Pantep Angchaisuksiri’s Transformative Leadership of the ISTH
-
Jul 10, 2026, 20:17Amy Pantaleo: How Staffing Shortages Are Changing Hemostasis Laboratories
-
Jul 10, 2026, 20:15Gene Nudelman: Early Hemorrhage Control Improves Patient Outcomes
-
Jul 10, 2026, 20:15Lee G.: Can We Transform Dengue Patient Management with Better Coagulation Assessment?
-
Jul 10, 2026, 20:13Shahin Alam: Is Your Coagulant Limiting Your Water Treatment Performance?
-
Jul 10, 2026, 20:12Ali Bozorgi: Our Meta-Analysis on Oral Anticoagulation After AF Ablation Featured in EP Europace
-
Jul 10, 2026, 15:34Joy Celebre: A New Opportunity in Hemostasis Leadership